ye7 casino slot
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Dentsply To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Dentsply between December 1, 2022 and November 6 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . [You may also click here for additional information] NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP , a leading national securities law firm, is investigating potential claims against DENTSPLY SIRONA Inc. (“Dentsply” or the “Company”) (NASDAQ: XRAY) and reminds investors of the January 27, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com . As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Dentsply targeted low-income people who did not have access to good oral hygiene education, a dentist, or dental insurance, which often meant patients signing up for Byte had underlying dental issues that would have made them ineligible for treatment; (2) the push for Byte growth and sales commissions caused sales employees to sell to contraindicated patients; (3) as a result of the above, the Byte patient onboarding workflow did not provide adequate assurance that contraindicated patients did not enter treatment; (4) before and during the Class Period, reports of Byte patient injuries were pouring in; (5) Dentsply knew that its Byte aligners were causing severe patient injuries for years but did little to investigate those injuries or notify the FDA; (6) Dentsply had no systems in place to notify the FDA of these injuries, which the Company is required to do within 30 days of learning of a problem; (7) the FDA had received a sharp uptick in reports of serious injuries from Byte patients; (8) as a result of the above, Dentsply materially overstated the goodwill value of Byte; (9) as a result of the above, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. The truth began to be revealed after markets closed on October 24, 2024, when Dentsply announced the “voluntary suspension of sales and marketing of its Byte Aligners and Impression Kits while the Company conducts a review of certain regulatory requirements related to these products.” Dentsply claimed that the Byte sales and marketing suspension was a “precautionary measure.” Dentsply further disclosed that it “expects to record non-cash charges for the impairment of goodwill within the range of $450-$550 million” for its Orthodontic and Implant Solutions segment. During a “Byte business update call” before markets opened on October 25, 2024, Chief Executive Officer (“CEO”) Simon D. Campion gave more context about the Byte suspension: “[I]n connection with our ongoing discussions with FDA, we have determined that our patient onboarding workflow may not provide adequate assurance that certain contraindicated patients do not enter treatment with Byte Aligners.” On this news, the price of Dentsply stock fell over 4%, from a closing price of $24.41 per share on October 24, 2024, to a closing price of $23.31 per share on October 25, 2024. The truth was revealed on November 7, 2024 when, before the markets opened, Dentsply reported its financial results for the third quarter of 2024, disclosing that Dentsply had “recorded a non-cash charge for the impairment of goodwill of ($495) million net of tax within the Orthodontic and Implant Solutions segment.” During the corresponding earnings call held later that day, CEO Campion further disclosed that although Dentsply was “not at a point in our analysis to make a definitive decision concerning Byte,” the Company was “thoroughly evaluating strategic options, which may include a discontinuation of some or all of this business.” On this news, the price of Dentsply stock fell over 28%, from a closing price of $23.98 per share on November 6, 2024, to a closing price of $17.26 per share on November 7, 2024, on extraordinary trading volume. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Dentsply’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the DENTSPLY SIRONA class action, go to www.faruqilaw.com/XRAY or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310) . Follow us for updates on LinkedIn , on X , or on Facebook . Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/de2601eb-12a6-4c86-acde-1ee2f3350b29NoneLAS VEGAS — If Texas coach Steve Sarkisian holds aloft the College Football Playoff trophy next month, that will be bad news for BetMGM Sportsbook. It would be similarly disappointing if any of the coaches at Boise State, Indiana or Arizona State end up celebrating a title with confetti falling all around them inside Atlanta's Mercedes-Benz Stadium. Wait, what? Texas has attracted a lot of money all season to go all the way, but those other schools provide the hope of a big payoff. The fifth-seeded Longhorns are the co-favorite at BetMGM with No. 1 and unbeaten Oregon at 7-2 odds; the other three are least 40-1, while Georgia is right behind Oregon and Texas as the next favorite. "These teams get hot and people just want to have a flyer on them," BetMGM trading manager Seamus Magee said. "They don't want to be standing there and not have a ticket on some of these long-shot teams." Expanding the playoff field from four to 12 teams this year meant more betting in general on college football and more varieties of wagering on the postseason. There were meaningful games played in the final month by not only Arizona State, Boise State and Indiana, but also SMU, Army and UNLV — a number of teams not always in the national title conversation. "It's one of the highest handles we've ever had on our national-championship market," Magee said. "We're in more states, for one, but the activity and the betting patterns we're seeing, it definitely feels a lot more than it has in years past." Magee said BetMGM has received action on both sides of the first-round game between 11th-seeded SMU and sixth-seeded Penn State, but the Mustangs have drawn notable action at DraftKings and Caesars Sportsbook. Money on SMU dropped Penn State from a 9-point favorite at DraftKings to 8 1/2. "Any time they've played a real good team, they've had trouble," Johnny Avello, DraftKings race and sports operations director, said of the Nittany Lions. "SMU shows that they're pretty good on both sides of the football and pretty resilient as a team. Always in the game. Always finds ways to fight back." Joey Feazel, who oversees football trading for Caesars, said much of the early betting in general was on underdogs. "Usually, you see the dog money for these teams come late, especially on the sharps' (professional bettors) side," Feazel said. Boise State, which as the third seed has a first-round bye, will be the underdog in its quarterfinal matchup with Penn State or SMU. The Broncos got into the field as the highest-ranked Group of Five champion, but Avello said that doesn't mean they are one of the nation's top 12 teams (they are ranked No. 8 by AP and No. 9 by CFP). Avello said BYU, Colorado and Miami — none of which made the playoff — all would be favored over them. "There are a lot of teams that aren't in the playoffs that would be favored," Avello said. "That's just not the way these playoffs work." Feazel said Boise State not being able to play at home on its blue carpet will be a notable disadvantage. Boise State's quarterfinal game will be at the Fiesta Bowl in Glendale, Arizona. "It will be all neutral," Feazel said. "It's a big step up in class for Boise." Instead of all the games being played in climate-controlled domes or warm-weather locales — as has been in the case in past postseasons — three of the four first-round matchups will take place in the Northeast and Midwest. While that might not make a difference when Notre Dame hosts in-state foe Indiana, Ohio State will be at home against Tennessee and SMU visits Penn State. BetMGM favors all four home teams by more than a touchdown. "You have to take the weather into account for some of these games," Magee said. "It's going to be really cool to see a team like Tennessee that will have to go up to Columbus, where it can get really cold. SMU has to go from Dallas to Happy Valley. That's definitely going to be one of the coldest games a lot of those kids have played in their lives." SMU was the last team in the field, getting the benefit of the doubt over Alabama. The Mustangs had one fewer defeat than the three-loss Crimson Tide, who did not appear in the SEC title game. SMU lost on a 56-yard field goal to Clemson in the ACC championship. The sportsbook operators said the Tide would be favored by 5-10 points if they met SMU on a neutral field. Get local news delivered to your inbox!Ubisoft is officially discontinuing XDefiant in 2025, the publisher announced Tuesday , with all new purchases and registrations being discontinued immediately. As part of the shutdown, the publisher plans to shut down its production studios in San Francisco and Osaka while ramping down its site in Sydney, with up to 277 employees losing their jobs. Roughly half of the XDefiant team will be assigned roles elsewhere. Chief Studios and Portfolio Officer Marie-Sophie de Waubert revealed the news in an email sent to Ubisoft employees that was subsequently posted online, saying that the shooter was "not able to attract and retain enough players in the long run to compete at the level we aim for in the very demanding free-to-play FPS market." The full message can be found below. XDefiant Executive Producer Mark Rubin also shared a message thanking fans and saying he was "heartbroken." He also shared refund details, saying that any purchases made within the last 30 days will be fully refunded and that those who purchases the Ultimate Founder's Pack will also get their money back. Refunds should happen automatically with 8 weeks, he said. XDefiant joins Concord as the latest service game to abruptly shutter not long after launch. Unlike Concord, though, XDefiant will be given a bit of grace, with its servers not due to shut down until June 3, 2025. Ubisoft also plans to go forward with releasing Season 3, though downloads and purchases will no longer be available. First announced in 2021, XDefiant endured several delays before finally launching in May. We wrote in our review , "XDefiant joins the free-to-play shooter crowd as a respectable competitive FPS built around various Ubisoft franchises, but little makes it really stand out." Despite middling reviews, XDefiant got off to a fast start, pulling in a million unique players within two and a half hours, but its momentum soon dissipated. In October, Rubin acknowledged that players numbers were down while denying persistent shutdown rumors . XDefiant's impending shutdown adds to Ubisoft's woes in 2024 , which has included lower-than-expected sales for major releases , delays , and other setbacks. Its share price collapse reportedly has the Guillemot family and Tencent considering taking the company private . It's far from the only publisher to struggle in 2024 though as game developers of all sizes have been racked by abrupt shutdowns and layoffs . Kat Bailey is IGN's News Director as well as co-host of Nintendo Voice Chat. Have a tip? Send her a DM at @the_katbot.
Speculation, not facts, used against terrorism suspect Harkat, his lawyer tells judgeDELRAY BEACH, Fla.--(BUSINESS WIRE)--Dec 12, 2024-- PanGIA Biotech–a pioneer in liquid biopsy technology–today announced its first international partnership, collaborating with Canary Oncoceutics (Canary Oncoceutics, Inc., Phoenix, AZ, and Canary Oncoceutics India Pvt Ltd, Tamil Nadu, India). This collaboration introduces the PanGIA ® Prostate Assay , the world’s first AI-integrated urine-based liquid biopsy for prostate cancer detection, marking its commercial debut in India. "Launching our patented PanGIA Prostate Assay in India marks an important milestone for our company and healthcare innovation. This non-invasive , accurate, and culturally sensitive diagnostic tool is poised to enhance early prostate cancer detection and improve patient outcomes," said Holly Magliochetti, CEO of PanGIA Biotech. "Partnering with Canary Oncoceutics enables us to bring life-changing technology to a population in need, reinforcing our commitment to saving lives, changing lives, and giving back by advancing healthcare equity." A Turning Point in Early Cancer Detection in India The World Health Organization's Global Cancer Observatory (GLOBOCAN) estimates that prostate cancer is a significant health concern for men in India. Hebert, et al reported that about 85 percent of prostate cancers in India were detected at late (III and IV) stage; in contrast to the U.S. where 15 percent of prostate cancer is diagnosed at late stage. These figures highlight the importance of early detection for improving outcomes and reducing mortality rates. “The only way to mitigate the harm caused by rising case numbers is to urgently set up systems for earlier diagnosis in Low and Middle Income Countries,” according to the Lancet Commission on Prostate Cancer (2024). “With this partnership agreement, we can offer a unique test to the medical community in India,” said Dr. Harry Lander, CEO and co-founder of Canary Oncoceutics, Inc. “Our extensive presence in India allows us to rapidly deploy the PanGIA Prostate Assay.” PanGIA Biotech is actively advancing its R&D pipeline, targeting ten additional cancers including lung, pancreatic, ovarian, and breast. The company is also focused on validating its multi-cancer assay and expanding its global impact through continued innovation, offering long-term growth potential for partners. About PanGIA Biotech PanGIA Biotech develops AI-integrated liquid biopsy technology designed for global scalability. The PanGIA ® platform is a transformative solution for detecting, monitoring, and managing diseases, including cancers as early as Stage 1. Powered by machine learning, this urine-based platform profiles biomolecular patterns to deliver accurate diagnostic insights. PanGIA’s technology is grounded in peer-reviewed research and R&D success, supported by patents to the company for global diagnostic development. With a steadfast commitment to research and innovation, PanGIA’s vision is to revolutionize disease detection and improve healthcare worldwide. For more information, visit www.PanGIABiotech.com . View source version on businesswire.com : https://www.businesswire.com/news/home/20241212361892/en/ CONTACT: Joy Capps Media@PanGIABiotech.com 843-730-3857 KEYWORD: FLORIDA ARIZONA UNITED STATES INDIA NORTH AMERICA ASIA PACIFIC INDUSTRY KEYWORD: OTHER HEALTH RADIOLOGY OTHER SCIENCE MEN RESEARCH ONCOLOGY ARTIFICIAL INTELLIGENCE MEDICAL DEVICES CONSUMER GENETICS STEM CELLS SCIENCE TECHNOLOGY CLINICAL TRIALS GENERAL HEALTH BIOTECHNOLOGY HEALTH HEALTH TECHNOLOGY SOURCE: PanGIA Biotech Copyright Business Wire 2024. PUB: 12/12/2024 03:05 PM/DISC: 12/12/2024 03:05 PM http://www.businesswire.com/news/home/20241212361892/en
Emi Martinez began the night by walking onto the field with his children and parading a pair of trophies for being the world’s best goalkeeper for the last two years. He finished it by producing an astonishing save that vindicated those awards. The Argentina international illuminated a 0-0 draw between his Aston Villa team and Juventus in the Champions League on Wednesday by plucking the ball from behind him and scooping it off the goal line to deny Francisco Conceição what could have been the winner. Replays showed the ball was almost entirely over the line before Martinez hooked it clear, and the goalkeeper was quickly congratulated by his teammates. No save by Martinez will ever beat the one he pulled off for Argentina in the last seconds of extra time in the 2022 World Cup final , denying France striker Randal Kolo Muani and keeping teammate Lionel Messi’s dream alive of finally winning soccer’s biggest prize. He might just have run it close. It was fitting he produced his wonder save against Juve on the night he showed off the two Yashin Trophies he claimed at the Ballon d’Or awards ceremony in each of the past two years. The most recent one came last month. As for Juventus goalkeeper Michele Di Gregorio, he finished the game relieved that what appeared to be a mistake in the final seconds of stoppage time didn't cost his team. Di Gregorio spilled a cross under pressure from Villa defender Diego Carlos and Morgan Rogers was there to poke the ball into the net. A goal was awarded by the on-field referee but after a two-minute check, it was ruled out for a foul on Di Gregorio by Carlos. AP soccer: https://apnews.com/hub/soccer
Young men swung to the right for Trump after a campaign dominated by masculine appealsIs Arcane canon in League of Legends? It’s a complicated question
Trump's picks for key positions in his second administrationMacron to name new French PM Friday after days of deadlock
